While they confirm that TGFβ-signalling mutations might enhance EMT and metastases in some CRC patients, they point out other subtypes in which TGF-βRII actively hinders EMT and metastases thus leading to a better prognosis [2]. This evidence concerns the gene TGFB1 and colorectal carcinoma.